

Attorney Docket No.: RSW86283US
Client Ref.: P17733 DrB/bin

Applicant: Kirschning et al.
PCT App. No.: PCT/EP2004/010700
Serial No.: 10/595,204
Filing/371 Date: Mar. 23, 2006
For: TLR2 ANTAGONISTIC ANTIBODY AND USE THEREOF
Group: TBD
Examiner: TBD
Confirmation No.: 4608

POWER OF ATTORNEY BY ASSIGNEE,
CHANGE OF CORRESPONDENCE ADDRESS
EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71
AND STATEMENT UNDER 37 C.F.R. 3.73(b)

Dear Sir:

Amgen Inc. states it is an assignee of a 50% interest in the above-identified subject application by virtue of one or more assignments:

- ☒ that was recorded on 2/28/07 at reel/frame 018940/0072.
☐ that is submitted herewith for recording.
☐ for which a copy thereof is attached.

Amgen Inc. hereby appoints the practitioners associated with **Customer Number 65159** and David W. Maher, Reg. No. 40,077 as its attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71.

Please **direct all correspondence** relative to this application to the address associated with Customer Number **65159** and direct all telephone calls to David W. Maher at (858) 228-7829.

I am authorized to act on behalf of Amgen Inc.

Signature:

Typed/Printed Name:

Title:

Date:

Robert L. Watt
Robert L. Watt

Vice President, LAW

October 1, 2007

